Providence CEO insists firm will produce Manitoba-backed vaccine
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Monthly Digital Subscription
$19 $0 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*No charge for 4 weeks then billed as $19 every four weeks (new subscribers and qualified returning subscribers only). Cancel anytime.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 11/05/2021 (1227 days ago), so information in it may no longer be current.
A Manitoba-backed company that’s attempting to develop a COVID-19 vaccine says it continues to pursue plans to produce the product in Canada despite tepid support from the federal government.
On Wednesday, Providence Therapeutics of Calgary announced “very favourable” results from Phase 1 clinical trials for its messenger RNA vaccine.
Premier, vaccine developer retreat after deal falls through
Posted:
NEITHER Premier Brian Pallister nor Providence Therapeutics would comment on the status of Manitoba’s deal with the Calgary company to develop a COVID-19 vaccine since its CEO suddenly announced last week that he’s leaving Canada.
“Within the class of mRNA vaccines… (which include the Pfizer and Moderna products) our data compares very favourably,” Providence chief executive officer Brad Sorenson said in an interview.
He maintained that his company remains committed to producing the vaccine in Canada.
Sorenson called a recent media report quoting him as saying that Providence was tired of getting “the runaround” from Ottawa and was ready to move the company overseas “a bit sensationalized.”
“We have the ability to produce 200 million doses in Canada a year between our partners, Northern RNA in Calgary and the Emergent Biosolutions in Winnipeg,” he said. “And we’re going to produce those vaccines.
“Whether those vaccines are used by Canadians or whether they’re used somewhere else in the world, we’re going to make them because the world needs them. We’re not going to shut down production in the middle of a pandemic.”
Once the COVID-19 crisis is over, however, is another matter, Sorenson said, adding he was quoted correctly that the company is “evaluating its strategic options outside of Canada right now.”
Manitoba has promised to making a non-refundable payment of $7.2 million to Providence, but the money won’t be paid until a final contract is signed.
Sorenson said he won’t sign a deal until he’s “entirely confident” his vaccine will receive regulatory approval in Canada.
“If the deal gets signed, it will likely get signed in the next two or three weeks,” he said of the Manitoba contract.
The province has arranged to receive two million doses of vaccine from Providence; its $7.2-million commitment represents a 20 per cent down payment on the value of the contract.
If Health Canada doesn’t approve the vaccine, the company would not be able to supply Manitoba or any other Canadian jurisdiction.
However, Sorenson said he’s confident in being able to obtain regulatory approval and buyers outside of Canada in any case. He said he’s already getting numerous inquiries about the vaccine from around the world.
He said he has been disappointed his company has not received more government support for his initiative in Canada, particularly from the federal government.
The office of federal Industry Minister François-Philippe Champagne said more than a month ago that Ottawa had invested $10 million to help Providence Therapeutics with its early trials, although Sorenson said Wednesday he’s received less than $5 million from Ottawa to date.
The federal government said it has only placed orders for vaccine candidates that a scientific panel has deemed most likely to be effective and timely enough to immunize Canadians.
“If the deal gets signed, it will likely get signed in the next two or three weeks.” — Brad Sorenson, chief executive officer at Providence Therapeutics
Meanwhile, Sorenson said he asked the federal government two months ago for 500 doses of Pfizer vaccine for a Phase 2 comparative trial that is set to begin in June. He has yet to receive an answer.
He said the trial will go ahead because he can obtain back-up supplies in a pinch.
Unless Health Canada agrees to an accelerated approval process — something it has yet to commit to — a new Providence vaccine will not be available until early 2022.
The company is confident demand will remain strong globally, and it’s also likely that further booster shots will be required in the future in Canada even after the population is fully vaccinated.
In a statement Wednesday, the Pallister government repeated its position that Canada needs a strong, secure domestic vaccine research and manufacturing sector to win the fight against COVID-19.
“That is why Manitoba took the proactive step of investing in a made-in-Canada COVID vaccine research and manufacturing initiative. Manitoba remains in regular discussions with domestic vaccine suppliers and researchers on potential opportunities for Canadians and Manitobans,” the province said.
larry.kusch@freepress.mb.ca
Larry Kusch
Legislature reporter
Larry Kusch didn’t know what he wanted to do with his life until he attended a high school newspaper editor’s workshop in Regina in the summer of 1969 and listened to a university student speak glowingly about the journalism program at Carleton University in Ottawa.
Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber.
Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
